Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Page: 119

Published Date: 22 Apr 2024

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

Age-related macular degeneration (AMD) is a progressive eye disease that affects the macula, a part of the retina responsible for central vision. The cells in the macula become damaged and begin to die, causing vision loss as a person ages. The disease is typically categorized into two types: dry age-related macular degeneration (AMD) and wet age-related macular degeneration (AMD). Dry AMD is more common and involves the formation of small, yellow deposits in the macula, while wet AMD is less common and involves the growth of abnormal blood vessels beneath the macula. In dry AMD, treatment options include vitamin supplements and lifestyle changes to reduce risk factors. In wet AMD, treatment involves medications that are injected into the eye to stop the growth of abnormal blood vessels. This treatment is called abnormal endothelial growth factor (anti-VEGF) therapy, and it works by blocking the protein that stimulates the growth of abnormal blood vessels.

According to our (Global Info Research) latest study, the global Age-Related Macular Degeneration (AMD) Treatment Drugs market size was valued at US$ 10400 million in 2023 and is forecast to a readjusted size of USD 15260 million by 2030 with a CAGR of 5.6% during review period.

The age-related macular degeneration (AMD) market trends are shaping the growth of the market. For instance rise in the adoption of age-related macular degeneration drugs (AMD) among the geriatric population suffering from age-related macular degeneration (AMD) drives the growth of the age-related macular degeneration (AMD) market size. For instance, according to the 2022 factsheet of World Health Organization, by 2030, 1 in 6 people in the world is projected to be aged 60 years or over, indicating a potential increase in the age-related macular degeneration (AMD) market size.

This report is a detailed and comprehensive analysis for global Age-Related Macular Degeneration (AMD) Treatment Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:
Global Age-Related Macular Degeneration (AMD) Treatment Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2019-2030
Global Age-Related Macular Degeneration (AMD) Treatment Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2019-2030
Global Age-Related Macular Degeneration (AMD) Treatment Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2019-2030
Global Age-Related Macular Degeneration (AMD) Treatment Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Age-Related Macular Degeneration (AMD) Treatment Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Age-Related Macular Degeneration (AMD) Treatment Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Ionis Pharmaceuticals, Inc, Bausch Health Companies Inc, Regeneron Pharmaceuticals Inc, Biogen, Novartis AG, Sanofi S.A., Bayer AG, Coherus Biosciences Inc, F. Hoffmann-La Roche Ltd, Apellis Pharmaceuticals Inc, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation
Age-Related Macular Degeneration (AMD) Treatment Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    Aflibercept
    Ranibizumab
    Others

Market segment by Application
    Hospital Pharmacy
    Retail Pharmacy
    Online Pharmacy

Major players covered
    Ionis Pharmaceuticals, Inc
    Bausch Health Companies Inc
    Regeneron Pharmaceuticals Inc
    Biogen
    Novartis AG
    Sanofi S.A.
    Bayer AG
    Coherus Biosciences Inc
    F. Hoffmann-La Roche Ltd
    Apellis Pharmaceuticals Inc
    AbbVie
    Pfizer Inc.
    Amgen Inc.
    Samsung Bioepis

Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Age-Related Macular Degeneration (AMD) Treatment Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Age-Related Macular Degeneration (AMD) Treatment Drugs, with price, sales quantity, revenue, and global market share of Age-Related Macular Degeneration (AMD) Treatment Drugs from 2019 to 2024.
Chapter 3, the Age-Related Macular Degeneration (AMD) Treatment Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Age-Related Macular Degeneration (AMD) Treatment Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Age-Related Macular Degeneration (AMD) Treatment Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Age-Related Macular Degeneration (AMD) Treatment Drugs.
Chapter 14 and 15, to describe Age-Related Macular Degeneration (AMD) Treatment Drugs sales channel, distributors, customers, research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope
    1.2 Market Estimation Caveats and Base Year
    1.3 Market Analysis by Type
        1.3.1 Overview: Global Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Aflibercept
        1.3.3 Ranibizumab
        1.3.4 Others
    1.4 Market Analysis by Application
        1.4.1 Overview: Global Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Hospital Pharmacy
        1.4.3 Retail Pharmacy
        1.4.4 Online Pharmacy
    1.5 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size & Forecast
        1.5.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019 & 2023 & 2030)
        1.5.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity (2019-2030)
        1.5.3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price (2019-2030)

2 Manufacturers Profiles
    2.1 Ionis Pharmaceuticals, Inc
        2.1.1 Ionis Pharmaceuticals, Inc Details
        2.1.2 Ionis Pharmaceuticals, Inc Major Business
        2.1.3 Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
        2.1.4 Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 Ionis Pharmaceuticals, Inc Recent Developments/Updates
    2.2 Bausch Health Companies Inc
        2.2.1 Bausch Health Companies Inc Details
        2.2.2 Bausch Health Companies Inc Major Business
        2.2.3 Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
        2.2.4 Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 Bausch Health Companies Inc Recent Developments/Updates
    2.3 Regeneron Pharmaceuticals Inc
        2.3.1 Regeneron Pharmaceuticals Inc Details
        2.3.2 Regeneron Pharmaceuticals Inc Major Business
        2.3.3 Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
        2.3.4 Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 Regeneron Pharmaceuticals Inc Recent Developments/Updates
    2.4 Biogen
        2.4.1 Biogen Details
        2.4.2 Biogen Major Business
        2.4.3 Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
        2.4.4 Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.4.5 Biogen Recent Developments/Updates
    2.5 Novartis AG
        2.5.1 Novartis AG Details
        2.5.2 Novartis AG Major Business
        2.5.3 Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
        2.5.4 Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.5.5 Novartis AG Recent Developments/Updates
    2.6 Sanofi S.A.
        2.6.1 Sanofi S.A. Details
        2.6.2 Sanofi S.A. Major Business
        2.6.3 Sanofi S.A. Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
        2.6.4 Sanofi S.A. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.6.5 Sanofi S.A. Recent Developments/Updates
    2.7 Bayer AG
        2.7.1 Bayer AG Details
        2.7.2 Bayer AG Major Business
        2.7.3 Bayer AG Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
        2.7.4 Bayer AG Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.7.5 Bayer AG Recent Developments/Updates
    2.8 Coherus Biosciences Inc
        2.8.1 Coherus Biosciences Inc Details
        2.8.2 Coherus Biosciences Inc Major Business
        2.8.3 Coherus Biosciences Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
        2.8.4 Coherus Biosciences Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.8.5 Coherus Biosciences Inc Recent Developments/Updates
    2.9 F. Hoffmann-La Roche Ltd
        2.9.1 F. Hoffmann-La Roche Ltd Details
        2.9.2 F. Hoffmann-La Roche Ltd Major Business
        2.9.3 F. Hoffmann-La Roche Ltd Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
        2.9.4 F. Hoffmann-La Roche Ltd Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.9.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
    2.10 Apellis Pharmaceuticals Inc
        2.10.1 Apellis Pharmaceuticals Inc Details
        2.10.2 Apellis Pharmaceuticals Inc Major Business
        2.10.3 Apellis Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
        2.10.4 Apellis Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.10.5 Apellis Pharmaceuticals Inc Recent Developments/Updates
    2.11 AbbVie
        2.11.1 AbbVie Details
        2.11.2 AbbVie Major Business
        2.11.3 AbbVie Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
        2.11.4 AbbVie Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.11.5 AbbVie Recent Developments/Updates
    2.12 Pfizer Inc.
        2.12.1 Pfizer Inc. Details
        2.12.2 Pfizer Inc. Major Business
        2.12.3 Pfizer Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
        2.12.4 Pfizer Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.12.5 Pfizer Inc. Recent Developments/Updates
    2.13 Amgen Inc.
        2.13.1 Amgen Inc. Details
        2.13.2 Amgen Inc. Major Business
        2.13.3 Amgen Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
        2.13.4 Amgen Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.13.5 Amgen Inc. Recent Developments/Updates
    2.14 Samsung Bioepis
        2.14.1 Samsung Bioepis Details
        2.14.2 Samsung Bioepis Major Business
        2.14.3 Samsung Bioepis Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
        2.14.4 Samsung Bioepis Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.14.5 Samsung Bioepis Recent Developments/Updates

3 Competitive Environment: Age-Related Macular Degeneration (AMD) Treatment Drugs by Manufacturer
    3.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Manufacturer (2019-2024)
    3.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Manufacturer (2019-2024)
    3.3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Manufacturer (2019-2024)
    3.4 Market Share Analysis (2023)
        3.4.1 Producer Shipments of Age-Related Macular Degeneration (AMD) Treatment Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2023
        3.4.2 Top 3 Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturer Market Share in 2023
        3.4.3 Top 6 Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturer Market Share in 2023
    3.5 Age-Related Macular Degeneration (AMD) Treatment Drugs Market: Overall Company Footprint Analysis
        3.5.1 Age-Related Macular Degeneration (AMD) Treatment Drugs Market: Region Footprint
        3.5.2 Age-Related Macular Degeneration (AMD) Treatment Drugs Market: Company Product Type Footprint
        3.5.3 Age-Related Macular Degeneration (AMD) Treatment Drugs Market: Company Product Application Footprint
    3.6 New Market Entrants and Barriers to Market Entry
    3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region
    4.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size by Region
        4.1.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Region (2019-2030)
        4.1.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Region (2019-2030)
        4.1.3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Region (2019-2030)
    4.2 North America Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030)
    4.3 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030)
    4.4 Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030)
    4.5 South America Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030)
    4.6 Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030)

5 Market Segment by Type
    5.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Type (2019-2030)
    5.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Type (2019-2030)
    5.3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Type (2019-2030)

6 Market Segment by Application
    6.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Application (2019-2030)
    6.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Application (2019-2030)
    6.3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Application (2019-2030)

7 North America
    7.1 North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Type (2019-2030)
    7.2 North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Application (2019-2030)
    7.3 North America Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size by Country
        7.3.1 North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Country (2019-2030)
        7.3.2 North America Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Country (2019-2030)
        7.3.3 United States Market Size and Forecast (2019-2030)
        7.3.4 Canada Market Size and Forecast (2019-2030)
        7.3.5 Mexico Market Size and Forecast (2019-2030)

8 Europe
    8.1 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Type (2019-2030)
    8.2 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Application (2019-2030)
    8.3 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size by Country
        8.3.1 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Country (2019-2030)
        8.3.2 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Country (2019-2030)
        8.3.3 Germany Market Size and Forecast (2019-2030)
        8.3.4 France Market Size and Forecast (2019-2030)
        8.3.5 United Kingdom Market Size and Forecast (2019-2030)
        8.3.6 Russia Market Size and Forecast (2019-2030)
        8.3.7 Italy Market Size and Forecast (2019-2030)

9 Asia-Pacific
    9.1 Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Type (2019-2030)
    9.2 Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Application (2019-2030)
    9.3 Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size by Region
        9.3.1 Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Region (2019-2030)
        9.3.2 Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Region (2019-2030)
        9.3.3 China Market Size and Forecast (2019-2030)
        9.3.4 Japan Market Size and Forecast (2019-2030)
        9.3.5 South Korea Market Size and Forecast (2019-2030)
        9.3.6 India Market Size and Forecast (2019-2030)
        9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
        9.3.8 Australia Market Size and Forecast (2019-2030)

10 South America
    10.1 South America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Type (2019-2030)
    10.2 South America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Application (2019-2030)
    10.3 South America Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size by Country
        10.3.1 South America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Country (2019-2030)
        10.3.2 South America Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Country (2019-2030)
        10.3.3 Brazil Market Size and Forecast (2019-2030)
        10.3.4 Argentina Market Size and Forecast (2019-2030)

11 Middle East & Africa
    11.1 Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Type (2019-2030)
    11.2 Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Application (2019-2030)
    11.3 Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size by Country
        11.3.1 Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Country (2019-2030)
        11.3.2 Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Country (2019-2030)
        11.3.3 Turkey Market Size and Forecast (2019-2030)
        11.3.4 Egypt Market Size and Forecast (2019-2030)
        11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
        11.3.6 South Africa Market Size and Forecast (2019-2030)

12 Market Dynamics
    12.1 Age-Related Macular Degeneration (AMD) Treatment Drugs Market Drivers
    12.2 Age-Related Macular Degeneration (AMD) Treatment Drugs Market Restraints
    12.3 Age-Related Macular Degeneration (AMD) Treatment Drugs Trends Analysis
    12.4 Porters Five Forces Analysis
        12.4.1 Threat of New Entrants
        12.4.2 Bargaining Power of Suppliers
        12.4.3 Bargaining Power of Buyers
        12.4.4 Threat of Substitutes
        12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain
    13.1 Raw Material of Age-Related Macular Degeneration (AMD) Treatment Drugs and Key Manufacturers
    13.2 Manufacturing Costs Percentage of Age-Related Macular Degeneration (AMD) Treatment Drugs
    13.3 Age-Related Macular Degeneration (AMD) Treatment Drugs Production Process
    13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel
    14.1 Sales Channel
        14.1.1 Direct to End-User
        14.1.2 Distributors
    14.2 Age-Related Macular Degeneration (AMD) Treatment Drugs Typical Distributors
    14.3 Age-Related Macular Degeneration (AMD) Treatment Drugs Typical Customers

15 Research Findings and Conclusion

16 Appendix
    16.1 Methodology
    16.2 Research Process and Data Source
    16.3 Disclaimer

Table of Figures

List of Tables
 Table 1. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
 Table 2. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
 Table 3. Ionis Pharmaceuticals, Inc Basic Information, Manufacturing Base and Competitors
 Table 4. Ionis Pharmaceuticals, Inc Major Business
 Table 5. Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
 Table 6. Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 7. Ionis Pharmaceuticals, Inc Recent Developments/Updates
 Table 8. Bausch Health Companies Inc Basic Information, Manufacturing Base and Competitors
 Table 9. Bausch Health Companies Inc Major Business
 Table 10. Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
 Table 11. Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 12. Bausch Health Companies Inc Recent Developments/Updates
 Table 13. Regeneron Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
 Table 14. Regeneron Pharmaceuticals Inc Major Business
 Table 15. Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
 Table 16. Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 17. Regeneron Pharmaceuticals Inc Recent Developments/Updates
 Table 18. Biogen Basic Information, Manufacturing Base and Competitors
 Table 19. Biogen Major Business
 Table 20. Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
 Table 21. Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 22. Biogen Recent Developments/Updates
 Table 23. Novartis AG Basic Information, Manufacturing Base and Competitors
 Table 24. Novartis AG Major Business
 Table 25. Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
 Table 26. Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 27. Novartis AG Recent Developments/Updates
 Table 28. Sanofi S.A. Basic Information, Manufacturing Base and Competitors
 Table 29. Sanofi S.A. Major Business
 Table 30. Sanofi S.A. Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
 Table 31. Sanofi S.A. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 32. Sanofi S.A. Recent Developments/Updates
 Table 33. Bayer AG Basic Information, Manufacturing Base and Competitors
 Table 34. Bayer AG Major Business
 Table 35. Bayer AG Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
 Table 36. Bayer AG Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 37. Bayer AG Recent Developments/Updates
 Table 38. Coherus Biosciences Inc Basic Information, Manufacturing Base and Competitors
 Table 39. Coherus Biosciences Inc Major Business
 Table 40. Coherus Biosciences Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
 Table 41. Coherus Biosciences Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 42. Coherus Biosciences Inc Recent Developments/Updates
 Table 43. F. Hoffmann-La Roche Ltd Basic Information, Manufacturing Base and Competitors
 Table 44. F. Hoffmann-La Roche Ltd Major Business
 Table 45. F. Hoffmann-La Roche Ltd Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
 Table 46. F. Hoffmann-La Roche Ltd Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 47. F. Hoffmann-La Roche Ltd Recent Developments/Updates
 Table 48. Apellis Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
 Table 49. Apellis Pharmaceuticals Inc Major Business
 Table 50. Apellis Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
 Table 51. Apellis Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 52. Apellis Pharmaceuticals Inc Recent Developments/Updates
 Table 53. AbbVie Basic Information, Manufacturing Base and Competitors
 Table 54. AbbVie Major Business
 Table 55. AbbVie Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
 Table 56. AbbVie Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 57. AbbVie Recent Developments/Updates
 Table 58. Pfizer Inc. Basic Information, Manufacturing Base and Competitors
 Table 59. Pfizer Inc. Major Business
 Table 60. Pfizer Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
 Table 61. Pfizer Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 62. Pfizer Inc. Recent Developments/Updates
 Table 63. Amgen Inc. Basic Information, Manufacturing Base and Competitors
 Table 64. Amgen Inc. Major Business
 Table 65. Amgen Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
 Table 66. Amgen Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 67. Amgen Inc. Recent Developments/Updates
 Table 68. Samsung Bioepis Basic Information, Manufacturing Base and Competitors
 Table 69. Samsung Bioepis Major Business
 Table 70. Samsung Bioepis Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
 Table 71. Samsung Bioepis Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 72. Samsung Bioepis Recent Developments/Updates
 Table 73. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Manufacturer (2019-2024) & (K Dose)
 Table 74. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Manufacturer (2019-2024) & (USD Million)
 Table 75. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Manufacturer (2019-2024) & (US$/Dose)
 Table 76. Market Position of Manufacturers in Age-Related Macular Degeneration (AMD) Treatment Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
 Table 77. Head Office and Age-Related Macular Degeneration (AMD) Treatment Drugs Production Site of Key Manufacturer
 Table 78. Age-Related Macular Degeneration (AMD) Treatment Drugs Market: Company Product Type Footprint
 Table 79. Age-Related Macular Degeneration (AMD) Treatment Drugs Market: Company Product Application Footprint
 Table 80. Age-Related Macular Degeneration (AMD) Treatment Drugs New Market Entrants and Barriers to Market Entry
 Table 81. Age-Related Macular Degeneration (AMD) Treatment Drugs Mergers, Acquisition, Agreements, and Collaborations
 Table 82. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Region (2019-2023-2030) & (USD Million) & CAGR
 Table 83. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Region (2019-2024) & (K Dose)
 Table 84. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Region (2025-2030) & (K Dose)
 Table 85. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Region (2019-2024) & (USD Million)
 Table 86. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Region (2025-2030) & (USD Million)
 Table 87. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Region (2019-2024) & (US$/Dose)
 Table 88. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Region (2025-2030) & (US$/Dose)
 Table 89. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Type (2019-2024) & (K Dose)
 Table 90. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Type (2025-2030) & (K Dose)
 Table 91. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Type (2019-2024) & (USD Million)
 Table 92. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Type (2025-2030) & (USD Million)
 Table 93. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Type (2019-2024) & (US$/Dose)
 Table 94. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Type (2025-2030) & (US$/Dose)
 Table 95. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Application (2019-2024) & (K Dose)
 Table 96. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Application (2025-2030) & (K Dose)
 Table 97. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Application (2019-2024) & (USD Million)
 Table 98. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Application (2025-2030) & (USD Million)
 Table 99. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Application (2019-2024) & (US$/Dose)
 Table 100. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Application (2025-2030) & (US$/Dose)
 Table 101. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Type (2019-2024) & (K Dose)
 Table 102. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Type (2025-2030) & (K Dose)
 Table 103. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Application (2019-2024) & (K Dose)
 Table 104. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Application (2025-2030) & (K Dose)
 Table 105. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Country (2019-2024) & (K Dose)
 Table 106. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Country (2025-2030) & (K Dose)
 Table 107. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Country (2019-2024) & (USD Million)
 Table 108. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Country (2025-2030) & (USD Million)
 Table 109. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Type (2019-2024) & (K Dose)
 Table 110. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Type (2025-2030) & (K Dose)
 Table 111. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Application (2019-2024) & (K Dose)
 Table 112. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Application (2025-2030) & (K Dose)
 Table 113. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Country (2019-2024) & (K Dose)
 Table 114. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Country (2025-2030) & (K Dose)
 Table 115. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Country (2019-2024) & (USD Million)
 Table 116. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Country (2025-2030) & (USD Million)
 Table 117. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Type (2019-2024) & (K Dose)
 Table 118. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Type (2025-2030) & (K Dose)
 Table 119. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Application (2019-2024) & (K Dose)
 Table 120. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Application (2025-2030) & (K Dose)
 Table 121. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Region (2019-2024) & (K Dose)
 Table 122. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Region (2025-2030) & (K Dose)
 Table 123. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Region (2019-2024) & (USD Million)
 Table 124. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Region (2025-2030) & (USD Million)
 Table 125. South America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Type (2019-2024) & (K Dose)
 Table 126. South America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Type (2025-2030) & (K Dose)
 Table 127. South America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Application (2019-2024) & (K Dose)
 Table 128. South America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Application (2025-2030) & (K Dose)
 Table 129. South America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Country (2019-2024) & (K Dose)
 Table 130. South America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Country (2025-2030) & (K Dose)
 Table 131. South America Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Country (2019-2024) & (USD Million)
 Table 132. South America Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Country (2025-2030) & (USD Million)
 Table 133. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Type (2019-2024) & (K Dose)
 Table 134. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Type (2025-2030) & (K Dose)
 Table 135. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Application (2019-2024) & (K Dose)
 Table 136. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Application (2025-2030) & (K Dose)
 Table 137. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Country (2019-2024) & (K Dose)
 Table 138. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity by Country (2025-2030) & (K Dose)
 Table 139. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Country (2019-2024) & (USD Million)
 Table 140. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Country (2025-2030) & (USD Million)
 Table 141. Age-Related Macular Degeneration (AMD) Treatment Drugs Raw Material
 Table 142. Key Manufacturers of Age-Related Macular Degeneration (AMD) Treatment Drugs Raw Materials
 Table 143. Age-Related Macular Degeneration (AMD) Treatment Drugs Typical Distributors
 Table 144. Age-Related Macular Degeneration (AMD) Treatment Drugs Typical Customers


List of Figures
 Figure 1. Age-Related Macular Degeneration (AMD) Treatment Drugs Picture
 Figure 2. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Type, (USD Million), 2019 & 2023 & 2030
 Figure 3. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Type in 2023
 Figure 4. Aflibercept Examples
 Figure 5. Ranibizumab Examples
 Figure 6. Others Examples
 Figure 7. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
 Figure 8. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Application in 2023
 Figure 9. Hospital Pharmacy Examples
 Figure 10. Retail Pharmacy Examples
 Figure 11. Online Pharmacy Examples
 Figure 12. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value, (USD Million): 2019 & 2023 & 2030
 Figure 13. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value and Forecast (2019-2030) & (USD Million)
 Figure 14. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity (2019-2030) & (K Dose)
 Figure 15. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Price (2019-2030) & (US$/Dose)
 Figure 16. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity Market Share by Manufacturer in 2023
 Figure 17. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Manufacturer in 2023
 Figure 18. Producer Shipments of Age-Related Macular Degeneration (AMD) Treatment Drugs by Manufacturer Sales ($MM) and Market Share (%): 2023
 Figure 19. Top 3 Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturer (Revenue) Market Share in 2023
 Figure 20. Top 6 Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturer (Revenue) Market Share in 2023
 Figure 21. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity Market Share by Region (2019-2030)
 Figure 22. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value Market Share by Region (2019-2030)
 Figure 23. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030) & (USD Million)
 Figure 24. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030) & (USD Million)
 Figure 25. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030) & (USD Million)
 Figure 26. South America Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030) & (USD Million)
 Figure 27. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030) & (USD Million)
 Figure 28. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity Market Share by Type (2019-2030)
 Figure 29. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value Market Share by Type (2019-2030)
 Figure 30. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Type (2019-2030) & (US$/Dose)
 Figure 31. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity Market Share by Application (2019-2030)
 Figure 32. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Application (2019-2030)
 Figure 33. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Application (2019-2030) & (US$/Dose)
 Figure 34. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity Market Share by Type (2019-2030)
 Figure 35. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity Market Share by Application (2019-2030)
 Figure 36. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity Market Share by Country (2019-2030)
 Figure 37. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value Market Share by Country (2019-2030)
 Figure 38. United States Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030) & (USD Million)
 Figure 39. Canada Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030) & (USD Million)
 Figure 40. Mexico Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030) & (USD Million)
 Figure 41. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity Market Share by Type (2019-2030)
 Figure 42. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity Market Share by Application (2019-2030)
 Figure 43. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity Market Share by Country (2019-2030)
 Figure 44. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value Market Share by Country (2019-2030)
 Figure 45. Germany Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030) & (USD Million)
 Figure 46. France Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030) & (USD Million)
 Figure 47. United Kingdom Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030) & (USD Million)
 Figure 48. Russia Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030) & (USD Million)
 Figure 49. Italy Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030) & (USD Million)
 Figure 50. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity Market Share by Type (2019-2030)
 Figure 51. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity Market Share by Application (2019-2030)
 Figure 52. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity Market Share by Region (2019-2030)
 Figure 53. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value Market Share by Region (2019-2030)
 Figure 54. China Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030) & (USD Million)
 Figure 55. Japan Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030) & (USD Million)
 Figure 56. South Korea Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030) & (USD Million)
 Figure 57. India Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030) & (USD Million)
 Figure 58. Southeast Asia Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030) & (USD Million)
 Figure 59. Australia Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030) & (USD Million)
 Figure 60. South America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity Market Share by Type (2019-2030)
 Figure 61. South America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity Market Share by Application (2019-2030)
 Figure 62. South America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity Market Share by Country (2019-2030)
 Figure 63. South America Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value Market Share by Country (2019-2030)
 Figure 64. Brazil Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030) & (USD Million)
 Figure 65. Argentina Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030) & (USD Million)
 Figure 66. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity Market Share by Type (2019-2030)
 Figure 67. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity Market Share by Application (2019-2030)
 Figure 68. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Quantity Market Share by Country (2019-2030)
 Figure 69. Middle East & Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value Market Share by Country (2019-2030)
 Figure 70. Turkey Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030) & (USD Million)
 Figure 71. Egypt Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030) & (USD Million)
 Figure 72. Saudi Arabia Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030) & (USD Million)
 Figure 73. South Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Value (2019-2030) & (USD Million)
 Figure 74. Age-Related Macular Degeneration (AMD) Treatment Drugs Market Drivers
 Figure 75. Age-Related Macular Degeneration (AMD) Treatment Drugs Market Restraints
 Figure 76. Age-Related Macular Degeneration (AMD) Treatment Drugs Market Trends
 Figure 77. Porters Five Forces Analysis
 Figure 78. Manufacturing Cost Structure Analysis of Age-Related Macular Degeneration (AMD) Treatment Drugs in 2023
 Figure 79. Manufacturing Process Analysis of Age-Related Macular Degeneration (AMD) Treatment Drugs
 Figure 80. Age-Related Macular Degeneration (AMD) Treatment Drugs Industrial Chain
 Figure 81. Sales Channel: Direct to End-User vs Distributors
 Figure 82. Direct Channel Pros & Cons
 Figure 83. Indirect Channel Pros & Cons
 Figure 84. Methodology
 Figure 85. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Ionis Pharmaceuticals, Inc
Bausch Health Companies Inc
Regeneron Pharmaceuticals Inc
Biogen
Novartis AG
Sanofi S.A.
Bayer AG
Coherus Biosciences Inc
F. Hoffmann-La Roche Ltd
Apellis Pharmaceuticals Inc
AbbVie
Pfizer Inc.
Amgen Inc.
Samsung Bioepis

Related Reports

Global Age-Related Macular Degeneration (AMD) Treatment Drugs Supply, Demand and Key Producers, 2024-2030

Global Age-Related Macular Degeneration (AMD) Treatment Drugs Supply, Demand and Key Producers, 2024-2030

date 22 Apr 2024

date Pharma & Healthcare

Age-related macular degeneration (AMD) is a progressive eye disease that affects the macula, a part of the retina responsible for central vision. The cells in the macula become damaged and begin to die, causing vision loss as a person ages. The disease is typically categorized into two types: dry age-related macular degeneration (AMD) and wet age-related macular degeneration (AMD). Dry AMD is more common and involves the formation of small, yellow deposits in the macula, while wet AMD is less common and involves the growth of abnormal blood vessels beneath the macula. In dry AMD, treatment options include vitamin supplements and lifestyle changes to reduce risk factors. In wet AMD, treatment involves medications that are injected into the eye to stop the growth of abnormal blood vessels. This treatment is called abnormal endothelial growth factor (anti-VEGF) therapy, and it works by blocking the protein that stimulates the growth of abnormal blood vessels.

Product Tags

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>